3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
15
Myeloid
7
Other hematologic neoplasm
6
Other neoplasm
3
Plasma cell
2
Dermatologic
2
Sarcoma
1
Genitourinary
1
Conditions
Melanoma
864
Lymphoma, T-Cell, Cutaneous
143
Uveal Melanoma
96
Skin Neoplasms
96
Mycosis Fungoides
95
Sezary Syndrome
81
Carcinoma, Basal Cell
76
Neoplasm Metastasis
68
Lymphoma
64
Lymphoma, Non-Hodgkin
63
Keratosis, Actinic
61
Neoplasms
57
Leukemia, Lymphocytic, Chronic, B-Cell
57
Carcinoma, Renal Cell
55
Carcinoma, Non-Small-Cell Lung
54
Lymphoma, B-Cell, Marginal Zone
53
Precursor Cell Lymphoblastic Leukemia-Lymphoma
52
Lymphoma, Mantle-Cell
52
Lymphoma, Large B-Cell, Diffuse
52
Lymphoma, Follicular
52
Hodgkin Disease
52
Lymphoma, Large-Cell, Immunoblastic
50
Carcinoma, Merkel Cell
50
Burkitt Lymphoma
49
Brain Neoplasms
46
Multiple Myeloma
44
Lymphoma, Large-Cell, Anaplastic
41
Recurrence
40
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
40
Breast Neoplasms
40
Interventions
cobomarsen
2
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Immune System Diseases
×
Dermatologic
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts
NCT03837457
2020-11-19
PRISM
miRagen Therapeutics, Inc.
Phase 2
Terminated
8 enrolled